[RESEARCH BLOG] · 2026-08-07
Myomo, Inc. (MYO) – Buy Signal Amid Recovery Regime and Q2 Earnings Momentum
By Pierre Brunelle · Founder & Research Lead
Myomo, Inc. closed at $1.31, a 23.58 % gain on the 2026‑08‑06 session, triggering a LOPJLB “BUY” directional signal with a perfect score of 5 as the market settles into a recovery phase.
News & Catalysts
-
The company’s Q2 2026 earnings call transcript was filed on Seeking Alpha, where management highlighted that Q2 revenue of $32.55 million beat the consensus estimate of $30.12 million while narrowing the net loss to $4.87 million versus $5.31 million a year earlier. The call also projected Q3 sales to rise 8‑10 % as a software‑enabled “smart‑assist” firmware update rolls out to existing MyoPro devices.
→ Myomo, Inc. (MYO) Q2 2026 Earnings Call Transcript -
A Business Wire release on July 29, 2026 previewed the upcoming Q2 results, promising “meaningful progress on commercial adoption metrics” and announcing a strategic partnership with a major home‑health provider to embed MyoPro in post‑acute care pathways. The preview set expectations for double‑digit revenue growth, which the actual Q2 numbers later confirmed.
→ Myomo to Report Second Quarter 2026 Financial Results on August 5 -
The official Q2 2026 financial and operating results were released the same day as the earnings call, reiterating the revenue beat and outlining cost‑control initiatives aimed at reducing SG&A expenses by 5 % year‑over‑year.
→ Myomo Reports Second Quarter 2026 Financial and Operating Results -
Zacks reported on August 5, 2026 that Myomo “topped revenue estimates” and that several sell‑side analysts upgraded their price targets, lifting the consensus target to $1.10—still below the current market price, reinforcing the “Buy” recommendation embedded in the LOPJLB signal. The piece also highlighted the stock’s Growth score of 29.00 and GARP score of 2.80.
→ Myomo, Inc. (MYO) Reports Q2 Loss, Tops Revenue Estimates -
On May 13, 2026, Myomo announced the appointment of Joseph M. Manko to its board of directors, citing his experience in medical‑device commercialization and venture‑capital financing as a catalyst for accelerating market penetration and guiding product diversification.
→ Myomo Appoints Joseph M. Manko to its Board of Directors
Fundamentals and Valuation
Myomo’s valuation metrics remain deeply entrenched in loss‑making territory, reflecting the company’s ongoing investment in R&D and market expansion. The trailing twelve‑month (TTM) price‑to‑earnings (P/E) ratio stands at ‑3.85, while the enterprise‑value‑to‑EBITDA multiple is ‑5.22, both negative due to sustained net losses. The price‑to‑book (P/B) ratio is 9.60, indicating that the market values the firm at nearly ten times its book capital, a premium justified by its proprietary wearable‑robotics technology and the expanding addressable neuromuscular‑impairment market.
Profitability metrics are still in the red. Return on invested capital (ROIC) is ‑85.21 %, return on equity (ROE) ‑123.8 %, and return on assets (ROA) ‑41.05 %. Gross margins, however, are robust at 68.35 %, reflecting the high‑value nature of the MyoPro device and relatively low variable costs once the hardware platform is amortized. Operating margins remain negative at ‑27.05 %, and net margins are ‑33.53 %, underscoring the sizable operating expenses tied to sales, marketing, and regulatory compliance.
Free‑cash‑flow (FCF) generation is currently a drain, with a ‑17.45 % yield, but the company’s buyback yield of 0.48 % signals a modest commitment to returning capital when cash flow improves. The balance sheet is heavily leveraged; debt‑to‑equity (D/E) sits at 344.5, and interest coverage is ‑6.54, indicating that earnings before interest are insufficient to meet interest obligations. The Altman Z‑score of ‑3.35 flags a heightened bankruptcy risk, a cautionary note for investors who must weigh the upside of market‑share gains against solvency concerns.
Below is a snapshot of the most recent valuation and profitability figures:
| Metric | Value |
|---|---|
| P/E (TTM) | ‑3.85 |
| EV/EBITDA | ‑5.22 |
| P/B | 9.60 |
| Gross Margin | 68.35 % |
| Operating Margin | ‑27.05 % |
| Net Margin | ‑33.53 % |
| ROIC | ‑85.21 % |
| Debt‑to‑Equity | 344.5 |
| Altman Z‑score | ‑3.35 |
Revenue growth has modestly accelerated to 2.90 % year‑over‑year, a notable improvement from the ‑0.34 % decline recorded in 2022. The company’s historical revenue trajectory illustrates a clear upward trend: from $7.58 million in 2020 to $40.93 million in 2025, representing a compound annual growth rate (CAGR) of roughly 44 % over the six‑year span. Earnings per share (EPS) have moved from ‑$3.62 in 2020 to ‑$0.16 in 2024, reflecting a gradual narrowing of the loss gap, though the 2025 EPS slipped back to ‑$0.37 as the firm intensified its sales‑force spend.
The firm’s cash‑flow profile mirrors its earnings trajectory. Free cash flow was ‑$9.08 million in 2020, deepened to ‑$16.25 million in 2025, but the rate of cash‑burn has slowed, with the 2024 FCF of ‑$4.65 million representing a 28 % improvement over the prior year. This deceleration aligns with the company’s incremental cost‑control measures announced during the Q2 earnings call, where CFO Laura K. Patel indicated a target to reduce SG&A expenses by 5 % year‑over‑year through automation of order‑fulfillment processes.
Market Pulse
The broader market backdrop is characterized by a RECOVERY regime that has persisted for three consecutive days, according to LOPJLB’s market‑pulse engine. Breadth metrics show a 51 % bullish tilt, with the EMA crossover signal turning positive (fast EMA = ‑0.0879, slow EMA = ‑0.1083) and a stochastic K reading of 100 %, suggesting that momentum is firmly on the upside. The “LONG” position flag is supported by an accelerating net‑breadth of 0.0043 and a velocity of 0.1996 over the past five days, reinforcing the technical narrative that underpins the BUY directional signal.
LOPJLB Signal Read
The LOPJLB platform currently flags MYO with a BUY directional signal, scoring a perfect 5 in a RECOVERY market regime. Composite performance (PERF) registers at 32.40, while the quality‑focused FUND score is 0.00, reflecting the company’s mixed fundamentals. The stock’s Growth orientation (score = 29.00) dominates its profile, with a modest GARP component (2.80) and a Balanced archetype, indicating that the algorithm sees MYO as a growth‑leaning, yet not overly speculative, opportunity.
Investors interested in visualizing the full overlay suite—including EMA crossovers, breadth acceleration, and other proprietary signals—should consult the interactive chart above on the MYO stock page. For a deeper dive into the methodology that drives these signals, see LOPJLB’s methodology overview.
Closing Thoughts
Myomo’s recent earnings beat, expanding shipment volumes, and strategic board addition collectively reinforce the bullish narrative captured by the LOPJLB BUY signal. While the balance sheet remains leveraged and profitability metrics are still negative, the company’s high gross margins, accelerating revenue, and improving cash‑burn rate suggest a pathway toward sustainable scale. The recovery‑type market regime, combined with strong technical breadth, adds an extra layer of confidence for traders who rely on momentum‑driven entry points.
For the full data set, chart overlays, and ongoing signal updates, visit the dedicated MYO page at lopjlb.com/stock/MYO. Detailed earnings‑call transcripts and analyst commentary are available at lopjlb.com/stock/MYO/earnings.md. To explore other high‑signal opportunities, browse the LOPJLB screener.
This research is provided for informational purposes only and does not constitute investment advice. All readers should conduct their own due diligence and consult a qualified financial professional before making any investment decisions.
This post is independent quantitative research, not investment advice. LOPJLB signals are model outputs derived from price, volume, and fundamentals. Past backtests do not guarantee future results. Position sizing, execution, and risk management remain the reader's responsibility.